【佳学基因检测】用于乳腺癌治疗的基于透明质酸的纳米药物递送系统：最新进展

肿瘤基因检测权威机构重要性

挖掘基因检测人员学科学习手册听到《Front Bioeng Biotechnol》在. 2022 Aug 24;10:990145.发表了一篇题目为《用于乳腺癌治疗的基于透明质酸的纳米药物递送系统：最新进展》肿瘤靶向药物治疗基因检测临床研究文章。该研究由Yufeng Jia, Siwen Chen, Chenyu Wang, Tao Sun, Liqun Yang 等完成。促进了肿瘤的精准治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及精准治疗临床研究内容关键词：

肿瘤靶向治疗基因检测临床应用结果

乳腺癌（BC）是全球女性最常见的恶性肿瘤，对药物的高耐药性和转移率是乳腺癌患者死亡的主要原因。将抗癌药物精准释放到肿瘤部位，可以提高疗效，减少对身体的副作用。天然聚合物作为治疗乳腺癌的药物载体引起了广泛的兴趣。透明质酸（HA）是一种天然多糖，具有优异的生物相容性、生物降解性和非免疫原性，是细胞外基质的重要组成部分。 HA 的 CD44 受体在乳腺癌细胞中过度表达，可靶向乳腺肿瘤。因此，许多研究人员开发了基于 HA 的 CD44 受体肿瘤靶向特性的纳米药物递送系统 (NDDS)。本综述探讨了近年来HA在乳腺癌NDDS中的应用。根据 NDDS 的结构组成，它们分为 HA NDDS、Modified HA NDDS 和 HA 混合 NDDS。

肿瘤发生与复发转移国际数据库描述：

Breast cancer (BC) is the most common malignancy among females worldwide, and high resistance to drugs and metastasis rates are the leading causes of death in BC patients. Releasing anti-cancer drugs precisely to the tumor site can improve the efficacy and reduce the side effects on the body. Natural polymers are attracting extensive interest as drug carriers in treating breast cancer. Hyaluronic acid (HA) is a natural polysaccharide with excellent biocompatibility, biodegradability, and non-immunogenicity and is a significant component of the extracellular matrix. The CD44 receptor of HA is overexpressed in breast cancer cells and can be targeted to breast tumors. Therefore, many researchers have developed nano drug delivery systems (NDDS) based on the CD44 receptor tumor-targeting properties of HA. This review examines the application of HA in NDDSs for breast cancer in recent years. Based on the structural composition of NDDSs, they are divided into HA NDDSs, Modified HA NDDSs, and HA hybrid NDDSs.